drugset / Trial / NCT04451239

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

NCT04451239

NaSingle-groupOpen-labelTreatment

Summary

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Timeline

Start
2020-06-30
Primary completion
2020-07
Completion
2020-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.5 % Topical
Subject Prednisolone Other / unclassified 1 % Topical

Indications